Your browser is no longer supported. Please, upgrade your browser.
NexImmune, Inc.
Index- P/E- EPS (ttm)- Insider Own0.30% Shs Outstand22.61M Perf Week10.68%
Market Cap354.79M Forward P/E- EPS next Y-2.45 Insider Trans0.00% Shs Float16.43M Perf Month21.55%
Income- PEG- EPS next Q-0.64 Inst Own43.10% Short Float1.79% Perf Quarter-0.25%
Sales- P/S- EPS this Y-42.80% Inst Trans0.17% Short Ratio5.06 Perf Half Y-18.20%
Book/sh4.86 P/B3.28 EPS next Y6.50% ROA- Target Price- Perf Year-
Cash/sh4.62 P/C3.45 EPS next 5Y- ROE- 52W Range10.10 - 28.00 Perf YTD-36.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.00% Beta-
Dividend %- Quick Ratio20.30 Sales past 5Y- Gross Margin- 52W Low58.02% ATR1.54
Employees44 Current Ratio20.30 Sales Q/Q- Oper. Margin- RSI (14)66.33 Volatility15.59% 10.22%
OptionableNo Debt/Eq0.00 EPS Q/Q-62.80% Profit Margin- Rel Volume23.82 Prev Close15.67
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume58.16K Price15.96
Recom2.00 SMA2015.35% SMA5025.00% SMA200-7.09% Volume1,385,563 Change1.85%
Apr-01-21Initiated Raymond James Outperform $30
Mar-09-21Initiated Cantor Fitzgerald Overweight $35
Mar-09-21Initiated Barclays Overweight $35
Sep-10-21 09:11AM  
Aug-10-21 03:54AM  
Aug-09-21 04:05PM  
Jul-27-21 04:01PM  
Jul-14-21 04:01PM  
Jun-16-21 04:29PM  
May-27-21 08:00AM  
May-19-21 04:21PM  
May-17-21 04:01PM  
May-12-21 04:51AM  
Apr-21-21 07:30AM  
Apr-13-21 12:04PM  
Mar-31-21 04:54PM  
Mar-02-21 04:01PM  
Feb-24-21 08:30AM  
Feb-23-21 08:00AM  
Feb-17-21 06:34PM  
Feb-11-21 10:03PM  
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trainer JohnChief Financial OfficerJul 08Option Exercise5.173,43217,74361,770Jul 09 04:19 PM
Trainer JohnChief Financial OfficerJun 08Option Exercise5.173,43217,74358,338Jun 09 04:06 PM
Trainer JohnChief Financial OfficerMay 08Option Exercise5.173,43217,74354,906May 19 04:16 PM
Trainer JohnChief Financial OfficerApr 08Option Exercise5.173,43217,74351,474May 19 04:16 PM
Trainer JohnChief Financial OfficerMar 10Option Exercise5.173,43217,74348,042Mar 12 02:00 PM
Jones KristiChief Operating OfficerFeb 17Buy17.0091115,48763,078Feb 19 04:30 PM
ZELDIS JEROME BExecutive VP of Research & DevFeb 17Buy17.005,88299,9945,882Feb 19 04:30 PM
Verstandig GrantDirectorFeb 17Buy17.00175,0002,975,000714,895Feb 19 04:25 PM
BARER SOL JDirectorFeb 17Buy17.0060,0001,020,0001,538,013Feb 19 04:20 PM